|
Damit wir auch wissen wovon Schlufti da redet :-) NEW YORK, GENEVA, and MONTREAL, Oct. 15 /PRNewswire/ -- New York based Artificial Life Inc. (OTC Bulletin Board: ALIF), a leading provider of award winning intelligent software robot (bot) technology and specialist for computational biotech applications, announced today that it has entered into a partnership agreement with the Swiss/Canadian privately held biotech company BeFutur Biotechnologies SA, a technology leader in stem cell research and regenerative medicine. The two companies have agreed to co-operate in the areas of -- stem cells research -- simulation and analysis of cell growth patterns -- regenerative medicine -- product and vaccine development "This is a great jump start for us in the biotech arena. Like us, BeFutur is a technology leader and an innovative and dynamically growing company with an enthusiastic founder and employees. We all are excited to co-operate with BeFutur to simulate cell growth patterns with our unique technology to speed up, improve and augment the manual lab research and product development at BeFutur. The potential of the combination of our simulation and data mining tools with the know-how and unique serum free cell technology of BeFutur is tremendous" said Eberhard Schoeneburg, CEO of Artificial Life. "We are delighted to announce our partnership with Artificial Life Inc., a leader in artificial life algorithms and simulations, with biotech applications. This alliance will further develop an outstanding technology platform that will improve human lives through advances in biotechnologies and the field of intelligent sciences. Our unique cell-culture technology in a serum-free medium, together with the exclusive cell growth simulation patterns developed by Artificial Life Inc., represent a tremendous step in enhancing the fields of biology and bio-mathematics, and hence obtaining efficient tools that will allow us to carry out a more precise and complete research line. Artificial Life Inc. entirely responds to our standards of quality and scientific credibility, which are the hallmarks of BeFutur philosophy" said Dr. Cyril Guey, founder and CEO of BeFutur Biotechnologies SA. "BeFutur Biotechnologies is honored to be associated with Artificial Life; their data mining and Alife simulation technology can be applied and adapted to all kinds of complex biotech data and stem cell development patterns. Our breakthrough results in stem cell research, combined with their algorithms derived from the study of living systems can have a tremendous impact in real life applications", said Carla-Maria Khanjian, Vice-President of BeFutur Biotechnologies SA. About Artificial Life Founded in 1994, Artificial Life, Inc. (OTC Bulletin Board: ALIF) develops, markets, and supports intelligent award winning and patent pending software robots and is a leading provider of data- and knowledge mining algorithms and biotech solutions. The company offers a variety of unique product suites for a wide variety of Internet based applications such as self-help, self-service, consultative selling, e-CRM, e-Finance and Mobile Computing. Major customers of Artificial Life include, among others, Advance Bank, Credit Suisse First Boston, Eagle Star, Liechtenstein Global Trust, MobilCom, Pioneer Investments, PricewaterhouseCoopers, UBS and ZDF. Artificial Life, Inc. is headquartered in New York City, NY, U.S.A, and maintains a subsidiary in Hong Kong. Detailed information about Artificial Life, Inc. and its products is available at http://www.artificial-life.com Contact: E.Schoeneburg, CEO Artificial Life, Inc. E-mail: es@artificial-life.com About BeFutur Biotechnologies Founded in 1998, BeFutur Biotechnologies is a privately-held Swiss biotech company with a very specialized R&D team. BeFutur is on the forefront of research for harvesting adult autologous stem cells. It is the only company in the world that uses a totally animal serum free medium, thereby avoiding any risk of rejection and contamination. Its unique technology is based on a stable cell-culture method, which harvests cells usable in future cell therapies. Its research activities remain in stem cell differentiation to tissue engineering, with a primary focus on tissue regeneration. BeFutur Biotechnologies S.A. is headquartered in Geneva, Switzerland, with subsidiaries in Montreal, Canada and Mougins, France. More information can be obtained at: http://www.befutur.com Contact: Carla-Maria Khanjian, VP, BeFutur Biotechnologies, Email: carla@befutur.com "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Artificial Life, Inc.`s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" described in the Company`s Annual Report or Forms 10-K or 10-Q for the most recently ended fiscal year and quarter. All information set forth in this press release is as of August 20, 2001, and Artificial Life, Inc. undertakes no duty to update this information unless required by law. BeFutur Biotechnologies is a registered trademark. SOURCE Artificial Life, Inc. Web Site: http://www.artificial-life.com |
|
| aus der Diskussion: | Artificial Life bankrott ? |
| Autor (Datum des Eintrages): | smile1 (19.10.01 20:16:09) |
| Beitrag: | 139 von 292 (ID:4681461) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |